A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Research output: Contribution to journalJournal articleResearchpeer-review

Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 mu g, 150 mu g, and 300 mu g) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 mu g dose seems sufficient to prevent hypoglycemia.
Original languageEnglish
JournalObesity Surgery
Pages (from-to)1605-1610
Number of pages6
Publication statusPublished - 2020

    Research areas

  • Gastric bypass, Hypoglycemia, Hyperglycemia, Pasireotide, Somatostatin analogs

ID: 230692191